The impact of mindfulness-based interventions on symptom burden, positive psychological outcomes, and biomarkers in cancer patients

Codie R Rouleau¹
Sheila N Garland²
Linda E Carlson³

¹Department of Psychology, Faculty of Arts, University of Calgary, Calgary, AB, Canada; ²Department of Family Medicine and Community Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; ³Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

Abstract: Research on the use of mindfulness-based stress reduction and related mindfulness-based interventions (MBIs) in cancer care has proliferated over the past decade. MBIs have aimed to facilitate physical and emotional adjustment to life with cancer through the cultivation and practice of mindfulness (ie, purposeful, nonjudgmental, moment-to-moment awareness). This descriptive review highlights three categories of outcomes that have been evaluated in MBI research with cancer patients – namely, symptom reduction, positive psychological growth, and biological outcomes. We also examine the clinical relevance of each targeted outcome, while describing recently published original studies to highlight novel applications of MBIs tailored to individuals with cancer. Accumulating evidence suggests that participation in a MBI contributes to reductions in psychological distress, sleep disturbance, and fatigue, and promotes personal growth in areas such as quality of life and spirituality. MBIs may also influence markers of immune function, hypothalamic–pituitary–adrenal axis regulation, and autonomic nervous system activity, though it remains unclear whether these biological changes translate to clinically important health benefits. We conclude by discussing methodological limitations of the extant literature, and implications of matching MBIs to the needs and preferences of cancer patients. Overall, the growing popularity of MBIs in cancer care must be balanced against scientific evidence for their impact on specific clinical outcomes.

Keywords: mindfulness-based intervention, cancer, mindfulness-based stress reduction, mindfulness-based cancer recovery, outcomes

Introduction

Cancer is a leading cause of mortality worldwide, with 1.7 million new diagnoses and 585,720 deaths estimated during 2014 in the United States alone.¹,² Diagnosis, treatment, and survivorship are associated with a complex array of stressors including treatment side effects; changes in daily activities; disrupted social, family, and occupational roles; and the possibility of cancer recurrence and death.³,⁴,⁵ To buffer the effects of these and other stressors, the use of integrative mind–body therapies for cancer care is common. Recent data suggest that 32% of cancer survivors report current or past use of mind–body interventions such as meditation, yoga, and stress management to promote emotional and physical well-being and to reduce psychological distress.⁶,⁷

One type of mind–body intervention that has been well studied in cancer populations is mindfulness-based stress reduction (MBSR), a program designed to assist individuals in coping with physical and/or emotional challenges through the cultivation and practice of mindfulness.⁸ The program is semimanualized, meaning that sessions are structured and follow general principles, but they also allow the interventionist
to flexibly adapt session content based on participant needs and concerns. Mindfulness is a concept rooted in ancient Buddhist tradition that refers to purposeful, nonjudgmental, moment-to-moment awareness. This is in contrast to the experience of automatically reacting to experience, ruminating about the past, and worrying about the future, which may be prominent in individuals facing a life-threatening diagnosis such as cancer. The ability to engage in mindful awareness is associated with improved psychological distress and physical health symptoms in populations with chronic illness, including cancer.

MBSR was first developed by Kabat-Zinn et al in the late 1970s to help relieve suffering among individuals with chronic pain, anxiety, and other unexplained medical symptomatology. The traditional MBSR program involves eight weekly 150-minute sessions consisting of didactic instruction, group discussion, formal meditation practice (e.g., body scan, sitting meditation, walking meditation, loving kindness), gentle hatha yoga, plus a 6-hour silent meditation retreat. Essential components also include regular home-based mindfulness meditation and the incorporation of mindfulness into everyday activities. This framework serves as the basis for various MBSR adaptations with various formats and durations, collectively called mindfulness-based interventions (MBIs), that have been used with cancer patients. Two formalized MBIs that have been evaluated in oncology populations include mindfulness-based cognitive therapy (MBCT), which combines the MBSR curriculum with principles of cognitive therapy and was originally intended for the treatment of depression, and mindfulness-based cancer recovery (MBCR), one of the most widely evaluated cancer-specific adaptations of MBSR that involves eight 90-minute group classes with content tailored to the unique stressors and experiences associated with cancer. We refer to programs as MBIs if they were developed from Kabat-Zinn’s original MBSR framework and if they do not involve only meditation or yoga.

The literature on MBIs for patients with cancer has been synthesized elsewhere several times between 2005 and 2015 in meta-analyses, literature reviews, and book chapters. The aim of this paper is to add to this literature by providing a nonsystematic, descriptive review of MBI outcomes that have been empirically evaluated in cancer populations, with a focus on recently published original studies to highlight research trends and novel applications. The process used to retrieve studies involved an initial search for review papers on MBIs for cancer patients using search terms such as “mindfulness”, “mindfulness-based interventions”, “mindfulness-based stress reduction”, “mindfulness-based cancer recovery”, “mindfulness-based cognitive therapy”, “cancer”, and/or “oncology” in PubMed, PsycINFO, and Google Scholar, followed by a search within reference lists for additional review papers. We then completed an additional search for original studies published since 2014 that had not been included in review articles. Readers are encouraged to consult existing review papers and original articles for more systematic details of methods, samples, and outcomes that have been evaluated in MBI studies.

We outline three categories of outcomes that have been most widely studied—symptom reduction, positive psychological outcomes, and biomarkers—and describe why each outcome might represent a suitable target of intervention in cancer care. Understanding the range of benefits individuals might experience following MBI participation will help ensure interventions are consistent with a particular patient’s goals, values, and clinical characteristics, which could impact adherence and outcomes. This review could serve as a springboard for future investigations into the following questions: which desired outcomes can be targeted by MBIs? And for whom might MBIs be well-suited?

Symptom reduction

Individuals with cancer are prone to multiple symptoms associated with the disease, its treatment, and comorbid conditions. Symptoms may include psychological distress, sleep disturbance, shortness of breath, nausea, diarrhea, pain, lymphedema, vasomotor symptoms, and anemia. MBIs may play an important role in helping patients manage mental and physical health symptoms, and in reducing the impact of cancer-related symptoms on overall functioning and quality of life. The most widely evaluated symptoms in MBI studies with cancer patients include psychological distress, sleep disturbance, and fatigue, so these are outlined below. It is noteworthy that preliminary evidence exists for the use of MBIs to reduce other cancer symptoms such as pain, sexual difficulties, and hot flashes and that MBIs have been widely used to alleviate some of these symptoms (especially pain) in noncancer populations.

Psychological distress

Individuals living with cancer commonly experience psychological distress throughout the illness trajectory. Psychological distress is a multidimensional concept that exists along a continuum, and is most commonly assessed using measures of affective states, symptoms of stress, anxiety, and depressed mood. It is estimated that 30%–43% of cancer
patients exceed clinical cutoffs for psychological distress on self-report instruments. Up to 38% meet diagnostic criteria for major depression and 18% meet criteria for an anxiety disorder, though estimates vary depending on the measurement method and cancer type. Psychological distress can interfere with the ability to cope with cancer and, while still very controversial, some research suggests that persistent high levels of distress may adversely impact cancer progression and survival.

Psychological distress also represents the most frequently evaluated outcome in clinical studies of MBIs with cancer populations. To our knowledge, six meta-analyses have been published to date that examine the association of MBI participation with measures of psychological distress in people living with cancer. Most recently, Zainal et al examined nine studies, including two randomized controlled trials (RCTs) that investigated 6- to 8-week MBIs among women with breast cancer. The results indicate medium to large pooled effects on symptoms of stress, depression, and anxiety. Medium to large effects are also reported in prior meta-analyses of MBIs among cancer patients for improvements in depressed mood and anxiety, perceived stress and mood disturbance, distress, as well as aggregated mental health outcomes (ie, anxiety, depressed mood, stress, and psychological components of quality of life). A recent RCT of the traditional MBSR program among 336 women with stage I–III breast cancer indicated that medium to large improvements in depressed mood and anxiety, relative to usual care, were maintained at the 12-month follow-up. Further, there is growing evidence that MBIs are superior to active control conditions on some measures of distress, including depressed mood, anxiety, and stress symptoms.

Narrative reviews and clinical practice guidelines suggest that there is strong evidence for the use of MBIs to improve symptoms of stress, anxiety, and depression among individuals coping with cancer. However, most original studies have utilized uncontrolled, pre-post designs; have primarily recruited early-stage, nonmetastatic breast cancer patients; and have measured affective symptoms using self-report rather than formal diagnostic procedures. In addition, heightened baseline distress is not consistently used as an inclusion criterion in MBI studies. It therefore remains unclear whether MBIs are appropriate for the treatment of anxiety and/or mood disorders in cancer patients, whether some results would be more pronounced if participants were screened for distress or, in pre–post studies, whether reductions in distress are attributable to the intervention. To date, no MBI studies have selectively recruited cancer patients with diagnosed depression or anxiety; however, there is evidence from pre–post studies in noncancer populations that MBIs are associated with large effects on anxious and depressive symptoms in patients with psychological disorders. Since 2014, there has been ongoing work to remedy some of these limitations by examining the use of MBIs to reduce distress in oncology samples with diagnoses other than breast cancer, relatively greater severity of illness, other phases of illness including end of life and survivorship, and with measurement of distress using randomized designs and comparison groups.

### Sleep disturbance

Sleep is a significant problem for many cancer patients. Prevalence estimates suggest that the risk of insomnia symptoms is increased two- to three-fold in cancer patients, and that symptoms persist for years following cancer treatment in up to 44% of patients. Sleep disturbances such as insomnia can be caused or worsened by treatment side effects, pain, and psychological distress that are common in cancer, and they can be maintained by maladaptive sleep behaviors, dysfunctional cognitions about sleep, and physiological arousal. Despite the common co-occurrence of insomnia with psychological distress, including anxiety and depression, insomnia symptoms represent a distinct clinical entity that may warrant its own focus in psychosocial interventions.

To capitalize upon potential benefits of mindfulness for alleviating disturbed sleep, a number of RCTs have tested the impact of MBIs on sleep parameters in oncology populations, including four published in 2014 alone. Some of these studies report associations between MBIs and improvements in self-reported insomnia severity, sleep quality, sleep onset latency and wake time after sleep onset, sleep difficulties/disturbance, and in actigraphic measures of sleep quality/quantity, with some changes observed 12 weeks following program completion. Associations between MBIs and improvements in sleep have not always been significant relative to active treatment and waitlist comparison groups, and some findings may not be significant after correction for potential type I error. It is possible that more robust results would be observed if patients were selected for pre-existing sleep difficulty, given that most trials have not involved the a priori decision to target sleep, but rather included sleep-related measures as ancillary outcomes of larger RCTs.

A notable exception is the recent study by Garland et al, in which all patients were required to meet research
and diagnostic criteria for insomnia. This study reported the results from a RCT comparing MBCR to cognitive–behavioral therapy for insomnia among 111 patients with various cancer diagnoses. This trial was unique in that patients chose to participate in order to address insomnia rather than to learn meditation skills; they were also blinded to the treatment options at study consent, and they were informed only about their own assigned intervention. A noninferiority analysis indicated post-treatment insomnia symptoms were less severe in participants who completed cognitive–behavioral therapy relative to those who completed MBCR; however, MBCR was noninferior to cognitive–behavioral therapy for improving insomnia severity at the 3-month follow-up, with both groups showing subthreshold insomnia symptoms. These findings suggest that while MBCR may be slower to take effect on disturbed sleep relative to cognitive–behavioral therapy, both treatments produce clinically significant improvements in sleep in the longer term.

In general, it appears that MBIs may represent a treatment option for cancer patients with sleep difficulties, and that the effect of MBIs on sleep can be significant in light of the chronicity of insomnia in many individuals (eg, a mean of 7 years insomnia duration in Garland et al). Although there are currently no evidence-based guidelines on the use of MBIs for improving sleep in cancer patients, presumably due to insufficient evidence to date, it is encouraging to see renewed interest in the use of MBIs for cancer-related sleep difficulties since the first sleep outcomes of a 6-week MBSR program in cancer patients were published in 2003. Additional, well-designed, adequately powered controlled trials are needed to further establish the effect of MBIs in patients with insomnia who seek out this form of treatment.

**Fatigue**

Another frequently investigated cancer symptom in MBI research has been cancer-related fatigue (CRF), a persistent pattern of tiredness and diminished energy that is inconsistent with changes in sleep or activity levels and interferes with day-to-day functioning. CRF is one of the most common and distressing symptoms of cancer, with prevalence estimates suggesting that 59%–100% of cancer patients experience fatigue, and that 9%–56% experience clinically significant CRF. For up to 40% of patients, problems with fatigue persist for months or years following cancer treatment.

Among studies that have evaluated fatigue as an outcome of MBIs in cancer populations, two RCTs that have specifically targeted fatigue as a primary outcome deserve mention. Johns et al examined an abbreviated MBI for reducing fatigue among 35 post-treatment cancer survivors with CRF. The intervention consisted of seven 2-hour classes that involved education about CRF, training and practice in mindfulness meditation, and gentle hatha yoga, as well as 20 minutes of daily home practice. Relative to a waitlist group, patients who completed the MBI reported lower fatigue severity, lower fatigue interference, and greater vitality postprogram and at 1-month follow-up. The results corresponded to large effects and persisted after correction for multiple comparisons and statistical adjustment for baseline fatigue, mindfulness skills, and participation in recent mental health treatment. It is also noteworthy that all participants were retained from baseline through to 1-month follow-up, intervention attendance was high (88%), and the interventionist was blind to patient outcomes. Similarly, van der Lee and Garssen randomized 100 post-treatment cancer patients with significant fatigue to either a waitlist control or to an eight-session program, modified from the original MBCT program described earlier, to include psychoeducation about CRF in the place of depression content and an added exercise on coping with interpersonal boundaries. Following adjustment for baseline fatigue, fatigue severity was lower in MBCT participants relative to controls, which corresponded to a large effect that was maintained at the 6-month follow-up.

These findings support the possibility of tailoring MBIs to alleviate CRF, and they are consistent with the conclusions of review articles suggesting that MBIs are likely to be effective in the treatment of CRF and that there is moderate evidence for the use of MBIs to alleviate CRF. However, MBIs for fatigue also need to be investigated among patients with more severe cancer, given that a recent nonrandomized feasibility study involving a small group of 19 women with metastatic breast cancer indicated that standard 8-week MBSR was not associated with reductions in CRF from baseline to 4 months postprogram. Future work is also needed to confirm the utility of fatigue-specific MBIs with larger samples and to examine potential biobehavioral mechanisms through which mindfulness might influence CRF.

**Positive psychological outcomes**

There is growing recognition that the prominent focus on pathological outcomes in psychosocial oncology overlooks potential experiences of personal growth and meaning-making that can arise from the cancer experience, which may serve as an important buffer to psychological distress. Similarly, it has been suggested that psychosocial...
Interventions in cancer populations should target and evaluate not just symptom reduction, but also positive psychological outcomes that may arise.\textsuperscript{13,43,91}

The most frequently evaluated positive psychosocial outcome in MBI research has been quality of life – that is, "individuals' perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards, and concerns".\textsuperscript{94,95} Musial et al\textsuperscript{96} reported on four single-arm studies and two RCTs representing 248 cancer patients with mixed diagnoses who had received some form of MBI.\textsuperscript{16,38,61,93–95} Overall, there was a small effect of these MBIs on postprogram quality of life. Improvements in self-reported general well-being were also observed 1 year following an 8-week MBI that included cognitive therapy elements in 47 patients with mixed cancer diagnoses.\textsuperscript{86} Consistent with these findings, clinical practice guidelines indicate that there is strong evidence that meditation practice, including formal MBI participation, is associated with improved quality of life in patients treated for breast cancer.\textsuperscript{38}

In addition to improvements in quality of life, several single-group studies and RCTs with cancer patients have demonstrated that MBIs are associated with positive changes in other areas such as spirituality, positive affect, meaningfulness, acceptance, comfort, happiness, relaxation, and post-traumatic growth.\textsuperscript{20,46,61,96} However, positive psychological outcomes of MBIs have not consistently been superior to usual care or active comparison groups.\textsuperscript{15,96} Pooled results from two RCTs with oncology populations indicate no significant group differences between MBIs and usual care in terms of spiritual well-being outcomes (ie, the quality of life dimension that involves a sense of purpose, peace of mind, and finding comfort in one's spiritual beliefs).\textsuperscript{15,23,61,97} In one of these two studies, though, breast cancer patients in 8-week standard MBSR did show significantly greater improvements in spirituality when compared to both usual care and a nutrition education condition, which were maintained relative to the active control at the 12-month follow-up.\textsuperscript{61}

As an example of a recent study that has evaluated positive psychological outcomes from MBIs, Thornton et al\textsuperscript{17} evaluated a 20-session intervention that incorporated MBSR with sessions focused on values-based goal setting, stress management, social support, expressive communication, sexuality, and health behaviors. Thirty-two women with recurrent breast or gynecological cancer received the intervention over a 7-month period. There were medium to large improvements from baseline to postprogram in terms of hope, mindfulness, positive affect, and quality of life. Interestingly, greater mindfulness and hope were related to lower mood disturbance, anxiety, and depressive symptoms, suggesting that positive psychological outcomes tend to co-occur with reductions in psychological distress.

Qualitative studies also help generate a subjective understanding of positive psychological benefits that cancer patients might experience from mindfulness training. Responses in interviews, focus groups, and open-ended questionnaires with oncology samples who completed mindfulness training (either on its own or as part of a structured MBI) reveal themes of spirituality, personal growth, optimism, peacefulness, confidence, acceptance, openness, connectedness, happiness, general satisfaction, and appreciation of the group process and shared experience.\textsuperscript{68,69,98–102} For example, Visser et al\textsuperscript{92} interviewed nine women with advanced breast cancer about their experiences during a group-based MBI that involved eight weekly 2.5-hour sessions and a 1-day silent retreat. Themes revealed in the qualitative interviews suggest that patients felt that mindfulness training led them to have greater awareness of their thoughts and feelings, increased acceptance of their health condition, improved energy, better communication with significant others, and social support from other participants.\textsuperscript{99} Similarly, van den Hurk et al\textsuperscript{104} interviewed six patients with lung cancer and five partners of lung cancer patients who had participated in a MBSR program that included psychoeducation about grief. Participants reported that mindfulness practice had initiated a positive process of change, characterized by experiences such as standing still (eg, relaxing, taking time for themselves), being aware, insight into thoughts and feelings, letting go, changing behavior, and acceptance. Existing quantitative and qualitative findings suggest that patients may achieve a number of positive psychological benefits as a result of MBI participation, although future research is needed to clarify inconsistent findings.

Biomarkers

In addition to lessening some of the symptoms associated with cancer and promoting personal growth, evidence is beginning to emerge that MBI participation is associated with alterations in potentially important biological markers of stress and health.\textsuperscript{12,55,103} Biomarkers that have been shown to change following participation by cancer patients in MBIs include measures of immune function,\textsuperscript{20,94,95,104–107} hypothalamic–pituitary–adrenal axis regulation,\textsuperscript{61,94,104–107} prostate-specific antigen levels,\textsuperscript{108} and autonomic nervous system activity;\textsuperscript{46,94,109} not all biological changes, however, were observed relative to control groups. Literature reviews have generally concluded that MBIs show small but significant effects on biomarkers and physical health.\textsuperscript{24,29} Matchim et al\textsuperscript{29} reviewed four studies of MBIs in cancer patients and reported a small significant
effect on biological outcomes in most studies,\textsuperscript{94,95,105,106} with the exception of a large effect of MBCR on cytokine production at 6- and 12-month follow-up in an uncontrolled study with breast and prostate cancer patients.\textsuperscript{94} Similarly, a review of eight studies reported that MBIs show a small effect on physical health parameters including biomarkers (eg, levels of cortisol and interleukin 6, natural killer cell activity) and physical symptoms (eg, self-reported gastrointestinal and neurologic issues) in cancer populations.\textsuperscript{24}

Since the publication of these literature reviews, two RCTs have investigated the impact of MBSR\textsuperscript{109} and MBCR\textsuperscript{111} on additional biomarkers – namely, telomere length and telomerase activity – in breast cancer patients. Telomeres are specialized structures that protect chromosome ends, with shorter telomere length associated with cellular aging, whereas telomerase is a ribonucleoprotein enzyme involved in telomere maintenance and elongation.\textsuperscript{112} Both studies report promising results, such that telomere length was maintained following MBCR relative to a minimal intervention control condition,\textsuperscript{113} and telomerase activity improved more in MBSR relative to usual care and was sustained at 12-week follow-up.\textsuperscript{110} These two studies add to the growing literature on the potential effects of MBIs on biomarkers of health, given that shorter telomere length and telomerase activity have been shown to predict cancer mortality.\textsuperscript{113–115}

Taken together, these findings suggest that various biological parameters may serve as subtle but significant markers of treatment response to MBIs, and they may represent mechanisms through which psychosocial function could impact physical health.\textsuperscript{25,116} However, it will be crucial in future research to ensure that immune–endocrine outcomes are straightforward to interpret and have relevance for health.\textsuperscript{117} For instance, whether enhanced natural killer cell function is desirable or not may depend on the type and stage of cancer, the phase of treatment, and the baseline level of this biomarker of immune system activity. Further, biomarker response to MBIs may differ as a function of patient sex, cancer type, and baseline biologic values.\textsuperscript{106,107,109} The causal pathways linking MBIs to both stress reduction and biological activity are also unclear, such that biological changes can be a cause and/or effect of behavioral comorbidities such as psychological distress, depressed mood, fatigue, and impaired sleep.\textsuperscript{103} Therefore, the relationship between biomarker response to MBIs and long-term health or cancer symptoms is not well understood.

Discussion and implications

MBIs have become increasingly popular programs to assist cancer patients as they navigate the experience of living with the disease. It is clear that the mindfulness approach is a versatile one, with an abundance of benefits that may arise from realizing that one can “slow down and see things as they are, without blinders, and learn ways to hold the strong emotions and sensations that arise”.\textsuperscript{12} In returning to the initial question of which desired outcomes can be targeted by MBIs, the most consistently demonstrated benefit in cancer and noncancer populations is reduced psychological distress (perhaps, in part, because it is also the most routinely assessed outcome).\textsuperscript{12,118} Additional benefits may include reductions in sleep disturbance and fatigue, as well as improvements in overall quality of life, positive well-being, and spirituality. There is also growing evidence that MBIs may influence biological parameters, though it remains to be seen whether or not the changes observed translate into clinically significant health benefits for the patient.

A commonly reported reason for the use of MBIs and other complementary therapies by cancer patients is to promote general self-care and wellness, though some patients also desire specific outcomes such as enhanced immune function and reduced pain, distress, and insomnia.\textsuperscript{6,119} This suggests the importance of using existing empirical data on patient outcomes to ensure MBIs are matched to patient needs and preferences. For example, an individual seeking improvements in distress, sleep, fatigue, and/or positive psychological well-being may be satisfied with the program given the demonstrated ability of MBIs to influence these outcomes. In contrast, it is less clear whether MBIs can influence other symptoms a patient might hope to alleviate, such as pain, sexual issues, nausea, or cognitive dysfunction.\textsuperscript{38}

It is also possible that MBI retention could be improved if relevant content is added to interventions that target specific symptoms. Among patients joining a MBI to treat insomnia, for example, it may be important to provide education about insomnia and evidence supporting the use of mindfulness practice for disturbed sleep. Additional research is needed to assess whether the addition of symptom-specific modules can favorably influence MBI uptake, adherence, and outcomes.

Though some patients may join MBIs with the hope of improving biological outcomes,\textsuperscript{4} it is currently premature to conclude that these interventions can influence variables such as immune function or cellular aging in clinically meaningful ways. Research on biomarker outcomes has shown small effects, inconsistent findings, and has yet to demonstrate links to health outcomes such as cancer progression and longevity. Therefore, it is important to ensure prospective MBI participants have realistic expectations about the biological outcomes they might achieve, while still appreciating that research on biomarkers may contribute to
our understanding about mechanisms of action and treatment response.\textsuperscript{107,110,120,121} It will be interesting for future studies to continue examining how biomarkers relate to changes in mindfulness and psychosocial outcomes, including symptom reduction and positive well-being.

In terms of general research limitations, high attrition from MBIs, lack of long-term follow-up, and non-RCT designs continue to be methodological issues in some studies.\textsuperscript{24,33} The majority of research on MBIs also involves relatively small samples of self-selecting, educated, middle-aged White women with breast cancer, which could limit generalizability to individuals with different symptoms, prognoses (eg, those in the palliative stage of cancer), sociodemographics (eg, males), and views about mindfulness.\textsuperscript{27,28,33} Although participation in MBIs may assist cancer patients in dealing with symptoms of distress, sleep disturbance, or fatigue, it is currently not clear whether these interventions are useful to those living with other symptoms. As well, since these types of interventions only appeal to a subset of patients, the utility of the broad application of MBIs to all cancer patients and survivors is unknown. In addition, variability across studies in terms of outcome measures, cancer stage, and intervention content makes it difficult to compare findings or evaluate the “active ingredients” of MBIs.\textsuperscript{25} Some authors have indicated a need for greater investigation of how MBIs compare to other efficacious interventions (eg, cognitive–behavioral therapy), and how various “doses” of MBI (eg, program duration, amount of daily mindfulness practice) compare in their ability to improve outcomes.\textsuperscript{12,34,70,122}

Recent and ongoing research shows promise in some of these areas. For example, Kenne Sarenmalm et al\textsuperscript{123} plan to perform a 5-year follow-up in a RCT of MBSR for psychological distress in breast cancer patients, which will provide relatively long-term data on MBI outcomes. Also, van den Hurk et al\textsuperscript{168} published a mixed methods pilot study on MBSR for lung cancer patients (53% men) and their partners, demonstrating the feasibility of delivering MBIs within a nonbreast cancer sample. There has also been methodological progress with respect to abbreviated and online versions of MBIs designed to reduce the burden of program participation,\textsuperscript{14,48,65,123} and the inclusion of partners or close significant others in MBIs.\textsuperscript{58,104,124,125} For example, Wood et al\textsuperscript{125} recently published a session-by-session protocol for adapting MBCT to the caregivers of cancer patients. Partner involvement could be of added value considering that partners commonly report psychological distress that is inter-related with patient distress, and that there is preliminary evidence for the idea that partner participation in MBIs can reduce caregiver burden.\textsuperscript{58,126,127}

Overall, the growing popularity of MBSR and other MBIs for cancer patients must be balanced against scientific evidence for their impact on specific clinical outcomes.\textsuperscript{122} With the potential appeal of mindfulness training as a panacea to promote all facets of health and well-being, clinicians must be aware of the current state of evidence for the use of MBIs to facilitate physical and emotional adjustment to cancer.

\section*{Acknowledgments}

Dr Linda E Carlson holds the Enbridge Research Chair in Psychosocial Oncology at the University of Calgary Cumming School of Medicine, cofunded by the Canadian Cancer Society Alberta/Northwest Territories Division and Alberta Cancer Foundation. Dr Sheila N Garland is a post-doctoral fellow funded by a Canadian Institutes for Health Research (CIHR) Bisby Fellowship. Codie R Rouleau is funded by a CIHR Doctoral Award and an Alberta Innovates Health Solutions (AIHS) Graduate Studentship.

\section*{Disclosure}

The authors report no conflicts of interest in this work.

\section*{References}


